Enveric Biosciences moves HQ to Cambridge, MA; advances EB-003 toward IND in 2026

Enveric Biosciences, Inc.

Effective Sept 2, 2025, principal executive offices changed to 245 First Street, 18th Floor, Cambridge, MA 02142.
Relocation aims to leverage Boston biotech hub for talent, collaboration, and capital access.
Lead candidate EB-003 (dual 5-HT2A/5-HT1B agonist) progressing toward IND; first-in-human trial anticipated in 2026.
EB-003 designed to provide neuroplastogenic benefits without hallucinatory effects.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.